MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab
Panelists discuss how long-term follow-up data from MajesTEC-1 demonstrates teclistamab’s sustained efficacy and safety profile while identifying optimal candidates based on factors like prior therapy exposure, disease characteristics, and fitness level.
EP: 1.Brief Overview of Therapeutic Landscape for R/R MM
EP: 2.Comparative Outcomes: Talquetamab vs Physician's Choice in R/R Multiple Myeloma
EP: 3.MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab
EP: 4.Elranatamab Dosing Strategies: Implications for Community Practice
EP: 5.Navigating Post–CAR T Progression: Therapy Selection and Targeting
EP: 6.Bispecific Therapies in Relapsed/Refractory Multiple Myeloma
EP: 7.ASH Top Takeaways of Bispecific Antibodies in R/R Multiple Myeloma
Video content above is prompted by the following:
- Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab
- Is there a patient population who would benefit most from this treatment regimen?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
